TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01275222
Drug: Imatinib 800mg/day (Glevec is the brand name for imatinib)
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth. In the phase II part of the study all patients received Glivec 600 mg/day, except for 2 patients who received Glivec at a dose of 800 mg/day. This dose was permitted in Phase II as it was found to be safe in Phase I.
Study: NCT04152382
Drug: LY3462817 - IV
Normalized name: Immunoglobulin g1, anti-(human programmed cell death protein 1) (human monoclonal ly3462817 .gamma.1-chain), disulfide with human monoclonal ly3462817 .kappa.-chain, dimer
DrugBank: Peresolimab (DB18874)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT04152382
Drug: LY3462817 - SC
Normalized name: Immunoglobulin g1, anti-(human programmed cell death protein 1) (human monoclonal ly3462817 .gamma.1-chain), disulfide with human monoclonal ly3462817 .kappa.-chain, dimer
DrugBank: Peresolimab (DB18874)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03591471
Drug: Benazepril Hydrochloride Tablets
Normalized name: Benazepril Hydrochloride Tablets
DrugBank: Benazepril (DB00542)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In controlled group, Benazepril Hydrochloride Tablets are used for both the light and serious type with the dosage of 5-10mg/d(10mg/d for children with weight above 30kg) ,12 weeks in total.
Study: NCT03591471
Drug: Dipyridamole Tab 25 MG
Normalized name: dipyridamole Oral Tablet
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In controlled group,Dipyridamole Tab 25 MG are used for both the light and serious type of HSPN with the dosage of 3mg/kg/d ,3 times a day,12 weeks in total.
Study: NCT02106091
Drug: AFM11
Normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 4 weeks.
Study: NCT01533389
Drug: Silodosin
Normalized name: Silodosin
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug: silodosin dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks~Arms: Placebo
Study: NCT03959358
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
Study: NCT03959358
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
Study: NCT02823431
Drug: lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03755102
Drug: Dacomitinib
Normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 1 Dacomitinib Dosing:~Dose level 1: Dacomitinib 45mg daily Dose level -1: Dacomitinib 30mg daily Dose level -2: Dacomitinib 15mg daily~Cohort 2 Dacomitinib Dosing:~Dose level 1: Dacomitinib 30 mg daily Dose level -1: Dacomitinib 15 mg daily
Study: NCT03755102
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In cohort 2, participants will begin on dacomitinib orally daily in combination with Osimertinib~Dose level Osimertinib Dosing:~Dose level 1: Osimertinib 80 mg daily Dose level -1: Osimertinib 40 mg daily
Study: NCT00634894
Drug: Femara
Normalized name: Femara
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg by mouth daily x 12 weeks
Study: NCT00075010
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg/m\^2 by vein over 1 hour times 10 days
Study: NCT00075010
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/kg given orally daily for 10 days
Study: NCT02894918
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180ug/0.5ml,hypodermic injection once a week
Study: NCT01220375
Drug: Vinorelbine, G-CSF, & Plerixafor
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients 1-10 receive 35 mg/m2 vinorelbine i.v. on day 1, G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
Study: NCT01220375
Drug: Vinorelbine and Plerixafor
Normalized name: Plerixafor
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients 11-20 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No G-CSF will be administered. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
Study: NCT01220375
Drug: G-CSF and Plerixafor
Normalized name: G-CSF
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients 21-30 receive G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No chemotherapy with vinorelbine will be gine on day 1. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
Study: NCT01220375
Drug: Vinorelbine & Plerixafor on day when CD34 count is at least 15'000 CD34+ cells/ml of peripheral blood
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients 31-40 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application at 08:00 AM, on the first day on which the CD34 count has risen to at least 15'000 CD34+ cells/ml of peripheral blood. Stem cell collection is initiated 4 hours later (at 12:00 PM) on this day. No G-CSF will be administered.
Study: NCT01565512
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A total of 100 mg bupivacaine (20 mL of 5 mg/mL solution) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
Study: NCT01565512
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A total of 20 mL on injectable saline(0.9% NS) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
Study: NCT01260636
Drug: Gadobenate Dimeglumine
Normalized name: Gadobenate Dimeglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 mmol/kg, single dose
Study: NCT01260636
Drug: Gadopentetate Dimeglumine
Normalized name: Gadopentetate Dimeglumine
DrugBank: Gadopentetic acid (DB00789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double dose of 0.2 mmol/kg
Study: NCT01055171
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg; Single Administration.
Study: NCT01685281
Drug: Metadoxine (MG01CI)
Normalized name: metadoxine
DrugBank: Metadoxine (DB16554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo
Study: NCT00043914
Drug: lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00381485
Drug: Mometasone furoate/formoterol (MF/F) combination
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
Study: NCT00381485
Drug: Mometasone furoate/formoterol (MF/F) combination
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
Study: NCT00381485
Drug: Mometasone furoate MDI (MF MDI)
Normalized name: Mometasone Furoate
DrugBank: Mometasone (DB00764)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MF 400 mcg via metered dose inhaler twice daily for 12 weeks
Study: NCT01235351
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype
Study: NCT01235351
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75 mg daily, 150 mg daily
Study: NCT03478358
Drug: 177Lu-DOTA-EB-TATE 1
Normalized name: DOTA-TATE
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-30 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
Study: NCT03478358
Drug: 177Lu-DOTA-TATE
Normalized name: DOTA-TATE
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
Study: NCT03478358
Drug: 177Lu-DOTA-EB-TATE 2
Normalized name: DOTA-TATE
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
Study: NCT03478358
Drug: 177Lu-DOTA-EB-TATE 3
Normalized name: DOTA-TATE
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
Study: NCT03478358
Drug: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine)
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and amino acids (lysine and arginine).
Study: NCT03478358
Drug: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine).
Study: NCT02967744
Drug: NSAID
Normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAIDs are among the most common pain treatments for patients with osteoarthritis.
Study: NCT00940225
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00307294
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
Study: NCT00307294
Drug: Doxil
Normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days
Study: NCT03182088
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will receive spinal anesthesia using Bupivacaine (10 mg).
Study: NCT01114425
Drug: raltegravir (Isentress)
Normalized name: raltegravir Oral Tablet [Isentress]
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: raltegravir (Isentress) 400 mg bid
Study: NCT01402050
Drug: CERVIDIL (Dinoprostone)
Normalized name: dinoprostone Vaginal Insert [Cervidil]
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: INDUCTION OF LABOR
Study: NCT02028221
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the duration of he intervention period.
Study: NCT02562053
Drug: Combined oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation
Study: NCT01155232
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Forteo (teriparatide)pen daily for 24 months
Study: NCT01661296
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six intralesional injections (one injection per week) of SSG 50mg/cm-2 area of lesions
Study: NCT00493324
Drug: alefacept
Normalized name: Alefacept
DrugBank: Alefacept (DB00092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular
Study: NCT00493324
Drug: polyvalent pneumococcal vaccine
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT01080534
Drug: Tacrolimus 5 mg Capsule
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Study: NCT02505997
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single 5 mg oral dose of midazolam syrup given in the AM on Day 1 and Day 8.
Study: NCT02505997
Drug: Delafloxacin
Normalized name: Delafloxacin
DrugBank: Delafloxacin (DB11943)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral 450 mg delafloxacin tablets given twice daily (Q12h) on Days 3 to 8
Study: NCT02407821
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose will be initiated at 5 mg daily. At two weeks, a safety and tolerability assessment will be performed, and if tolerated, the dose will be increased to 10 mg daily. At 24 weeks, the medication will be titrated downwards to 5 mg daily for a further two weeks before discontinuation.
Study: NCT00352560
Drug: Irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 300 mg, once daily, 30 days.
Study: NCT02324569
Drug: SYR-472
Normalized name: petrolatum 0.472 MG/MG
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYR-472 tablets
Study: NCT00990236
Drug: Enoxaparin dose adjusted Lovenox based on TEG
Normalized name: enoxaparin Injectable Solution [Lovenox]
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R \< 1.0 min - increase dose by 10 mg BID; delta-R \>/= 1.0 min and \</= 2.0 min - no change; delta-R \> 2.0 min - decrease dose by 10 mg BID.
Study: NCT00990236
Drug: Enoxaparin 30 mg BID
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin dose of 30 mg twice a day without any adjustments
Study: NCT01489488
Drug: Riociguat (BAY63-2521)
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of 2.4 milligram (mg) riociguat (BAY63-2521) as pediatric high-concentration suspension (0.15 mg per milliliter \[mg/mL\], i.e. 16 mL) under fasting conditions
Study: NCT01489488
Drug: Riociguat (BAY63-2521)
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of 2.4 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 16 mL) under fed conditions
Study: NCT01489488
Drug: Riociguat (BAY63-2521)
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of 0.3 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 2 mL) under fasting conditions
Study: NCT01489488
Drug: Riociguat (BAY63-2521)
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of 0.15 mg riociguat as pediatric low-concentration suspension (0.03 mg/mL, i.e. 5 mL) under fasting conditions
Study: NCT01489488
Drug: Riociguat (BAY63-2521)
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of riociguat immediate release (IR) tablet 1 mg under fasting conditions
Study: NCT00452348
Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
Study: NCT01523860
Drug: Rituximab, Mitoxantrone, Bendamustine
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration
Study: NCT03684395
Drug: DOACs: Rivaroxaban, Dabigatran, Apixaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
Study: NCT00205738
Drug: Risperidone, Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04988646
Drug: Acyclovir 200 MG
Normalized name: acyclovir 200 MG
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered with 240 mL of water
Study: NCT04988646
Drug: Acyclovir 400 MG
Normalized name: acyclovir 400 MG
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered with 240 mL of water
Study: NCT04988646
Drug: Zovirax 200 MG Tablet
Normalized name: acyclovir 200 MG [Zovirax]
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered with 240 mL of water
Study: NCT00452348
Drug: Fluticasone propionate 250 mcg BID
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 250 mcg BID
Study: NCT04988646
Drug: Zovirax 400 MG Tablet
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered with 240 mL of water
Study: NCT02049281
Drug: Vintafolide
Normalized name: vintafolide
DrugBank: Vintafolide (DB05168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
Study: NCT00005045
Drug: carboxyamidotriazole
Normalized name: Carboxyamidotriazole
DrugBank: Carboxyamidotriazole (DB11960)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01275664
Drug: Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV and PO
Study: NCT01275664
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IP
Study: NCT01275664
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IP
Study: NCT01275664
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01275664
Drug: Granisetron Transdermal Patch
Normalized name: granisetron Transdermal System
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apply one patch to upper arm
Study: NCT04254471
Drug: carboplatin + etoposide
Normalized name: Carboplatin
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin and etoposide are background treatment.
Study: NCT01559727
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
Study: NCT01559727
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day
Study: NCT00101959
Drug: Rebif
Normalized name: Rebif
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01559727
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day
Study: NCT00889486
Drug: TZP-102
Normalized name: TZP-102
DrugBank: TZP-102 (DB16129)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03789006
Drug: Antithymocyte Immunoglobulin (Rabbit)
Normalized name: antithymocyte immunoglobulin (rabbit)
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction agent for living donor kidney transplantation
Study: NCT03789006
Drug: Interleukin 2 Receptor Antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Induction agent for living donor kidney transplantation
Study: NCT00615667
Drug: tacrolimus (FK506)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
Study: NCT00599924
Drug: sunitinib + FOLFOX
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 37.5 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
Study: NCT00599924
Drug: sunitinib + FOLFOX
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
Study: NCT00599924
Drug: sunitinib + FOLFOX
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg sunitinib + modified FOLFOX6 ( CRC, only Schedule 2/2)
Study: NCT00599924
Drug: sunitinib + FOLFOX
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 37.5 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
Study: NCT00599924
Drug: sunitinib + FOLFOX
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg sunitinib + modified FOLFOX6 (Schedule 4/2)